
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A new study models the impact of 4 key public health interventions on global HCV burden to see if WHO elimination targets are realistic.



